Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Depreciation: 2022-2024

Historic Accumulated Depreciation for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $8.8 million.

  • Stoke Therapeutics' Accumulated Depreciation rose 32.63% to $8.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.8 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of $8.8 million for FY2024, which is 32.63% up from last year.
  • Per Stoke Therapeutics' latest filing, its Accumulated Depreciation stood at $8.8 million for FY2024, which was up 32.63% from $6.7 million recorded in FY2023.
  • Stoke Therapeutics' Accumulated Depreciation's 5-year high stood at $8.8 million during FY2024, with a 5-year trough of $4.2 million in FY2022.
  • Moreover, its 3-year median value for Accumulated Depreciation was $6.7 million (2023), whereas its average is $6.6 million.
  • Data for Stoke Therapeutics' Accumulated Depreciation shows a peak YoY soared of 58.57% (in 2023) over the last 5 years.
  • Stoke Therapeutics' Accumulated Depreciation (Yearly) stood at $4.2 million in 2022, then spiked by 58.57% to $6.7 million in 2023, then surged by 32.63% to $8.8 million in 2024.